Refractory Multiple Myeloma

Oncology
5
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
IberdomidePhase 2
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
total marrow irradiationPhase 1/21 trial
Active Trials
NCT00112827CompletedEst. Feb 2019
Cartesian Therapeutics
1 program
1
Descartes-15Phase 11 trial
Active Trials
NCT06304636TerminatedEst. Nov 2025
Alliance Pharmaceuticals
1 program
1
IbrutinibPhase 1Small Molecule1 trial
Active Trials
NCT03702725Completed14Est. Oct 2024
Karyopharm Therapeutics
1 program
1
SelinexorPhase 11 trial
Active Trials
NCT04519476UnknownEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
City Therapeuticstotal marrow irradiation
Cartesian TherapeuticsDescartes-15
Karyopharm TherapeuticsSelinexor
Alliance PharmaceuticalsIbrutinib

Clinical Trials (4)

Total enrollment: 14 patients across 4 trials

NCT00112827City Therapeuticstotal marrow irradiation

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Start: Nov 2004Est. completion: Feb 2019
Phase 1/2Completed
NCT06304636Cartesian TherapeuticsDescartes-15

Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma

Start: Jun 2024Est. completion: Nov 2025
Phase 1Terminated
NCT04519476Karyopharm TherapeuticsSelinexor

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Start: Nov 2020Est. completion: Dec 2023
Phase 1Unknown
NCT03702725Alliance PharmaceuticalsIbrutinib

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Start: Aug 2019Est. completion: Oct 202414 patients
Phase 1Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)